A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Summary

This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.

Timeline

Start

2019-12-20

Primary completion

2023-05-08

Completion

2023-05-08

Outcome

Outcome not reported

Stopped: “Sponsor insolvency”

Drugs

Indications